CytRx Corp. (CYTR)

0.55
NASDAQ : Health Technology
Prev Close 0.57
Day Low/High 0.53 / 0.58
52 Wk Low/High 0.53 / 2.35
Avg Volume 135.00K
Exchange NASDAQ
Shares Outstanding 33.64M
Market Cap 19.18M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CytRx Corporation Reports Third Quarter 2018 Financial Results

CytRx Corporation Reports Third Quarter 2018 Financial Results

Quarter Marked by Centurion's Filing of a Provisional Patent for Breakthrough Personalized Medicine Companion Diagnostic to Accompany LADR Assets

Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline

Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline

Aldoxorubicin Being Studied in NantCell Clinical Trials in Combination with Immune-Based Therapy for the Treatment of Squamous Cell Carcinoma, Metastatic Pancreatic and Triple Negative Breast Cancers

CytRx To Hold Third Quarter 2018 Financial Results Conference Call And Webcast On Friday, November 2, 2018

CytRx To Hold Third Quarter 2018 Financial Results Conference Call And Webcast On Friday, November 2, 2018

LOS ANGELES, Oct. 29, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will report financial results for the quarter ended September 30, 2018 on...

CytRx Corporation To Present At The 2018 MicroCap Conference

CytRx Corporation To Present At The 2018 MicroCap Conference

LOS ANGELES, Sept. 25, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr.

CytRx Corporation Announces Receipt Of Milestone Payment From Orphazyme A/S

CytRx Corporation Announces Receipt Of Milestone Payment From Orphazyme A/S

Orphazyme Milestones Payments Could Deliver up to $120 Million, Plus Royalties

CytRx Corporation To Present At The H.C. Wainwright & Co. 20th Annual Global Investment Conference In New York City September 4-6, 2018

CytRx Corporation To Present At The H.C. Wainwright & Co. 20th Annual Global Investment Conference In New York City September 4-6, 2018

LOS ANGELES, Aug. 27, 2018 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr.

CytRx Corporation Reports Second Quarter 2018 Financial Results

CytRx Corporation Reports Second Quarter 2018 Financial Results

Substantial Reduction in CytRx Cash Burn Rate This Quarter

CytRx Corporation Pays Off Balance Of Outstanding Debt

CytRx Corporation Pays Off Balance Of Outstanding Debt

LOS ANGELES, Aug. 1, 2018 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has made the final scheduled payment under a long-term loan facility...

CytRx Corporation To Hold Second Quarter 2018 Financial Results Conference Call And Webcast On Monday, August 6, 2018

CytRx Corporation To Hold Second Quarter 2018 Financial Results Conference Call And Webcast On Monday, August 6, 2018

LOS ANGELES, July 30, 2018 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will report financial results for the quarter ended June 30, 2018 on...

CytRx Announces Centurion BioPharma Corporation's Filing Of A Provisional Patent Application

CytRx Announces Centurion BioPharma Corporation's Filing Of A Provisional Patent Application

Breakthrough Personalized Medicine Companion Diagnostic Filed for its Albumin-binding Drug Candidates

CytRx Corporation Announces Expiration Of Outstanding Warrants

CytRx Corporation Announces Expiration Of Outstanding Warrants

Warrants for 3.2 Million Common Shares Expired July 20, 2018

CytRx Corporation To Present At The Singular Research Summer Solstice 2018 Conference

CytRx Corporation To Present At The Singular Research Summer Solstice 2018 Conference

LOS ANGELES, July 16, 2018 /PRNewswire/ --  CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr.

CytRx Corporation Highlights Aldoxorubicin Included In New NantCell Inc. Triple Negative Breast Cancer Clinical Trial

CytRx Corporation Highlights Aldoxorubicin Included In New NantCell Inc. Triple Negative Breast Cancer Clinical Trial

This New Trial Represents the Third NantCell Study Evaluating Aldoxorubicin Combined with Immunotherapy or Cell-Based Therapy

CytRx Corporation Joins Russell Microcap® Index

CytRx Corporation Joins Russell Microcap® Index

LOS ANGELES, June 25, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has been added to the Russell Microcap ® Index, effective upon the market...

CytRx Corporation Highlights Review Of NantCell Inc's Aldoxorubicin Published In Future Oncology

CytRx Corporation Highlights Review Of NantCell Inc's Aldoxorubicin Published In Future Oncology

Clinical studies with aldoxorubicin demonstrated increased progression-free survival and tumor response with low cardiotoxicity

Interesting CYTR Call Options For March 2018

Interesting CYTR Call Options For March 2018

Investors in CytRx Corp saw new options begin trading today, for the March 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Goodbye CytRx, Your Game Is Over

Goodbye CytRx, Your Game Is Over

Hope springs eternal, until it's dashed on the rocks and buried at sea.

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

First Week of CYTR September 15th Options Trading

First Week of CYTR September 15th Options Trading

Investors in CytRx Corp saw new options begin trading this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA

CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA

CytRx announced a plan Tuesday to seek U.S. marketing approval of aldoxorubicin based more on hocus-pocus than credible study results.

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.

24-Hour Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation

24-Hour Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation

Law Offices of Howard G. Smith reminds investors of the upcoming  September 23, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise...

GPM Reminds Investors Of The September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation And Encourages Investors To Contact The Firm

GPM Reminds Investors Of The September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") reminds investors of the September 23, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise...

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of CytRx Corporation ("CytRx" or the "Company") (NASDAQ:CYTR )...

TheStreet Quant Rating: D- (Sell)